CDC Panel Endorses Broader Use of Pfizer and Merck Pneumococcal Vaccines

In a significant move aimed at enhancing public health, a panel of experts from the Centers for Disease Control and Prevention (CDC) has recommended the wider utilization of pneumococcal vaccines developed by Pfizer and Merck. This decision is seen as a pivotal step in combating pneumococcal disease, which can lead to serious infections like pneumonia, meningitis, and bloodstream infections.

Continue reading